![](https://investorshub.advfn.com/uicon/716239.png?cb=1669318942)
Thursday, May 02, 2024 3:10:46 PM
May 02, 2024
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.
"We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “A core focus of our business strategy is developing novel technology and a strong IP portfolio. This innovative technology will empower healthcare providers with the ability to adapt treatment plans as needed, ultimately leading to improved patient care and outcomes for critically ill children and neonates.”
Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This development effort is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design and development of a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.
Nuwellis is committed to developing life-saving technologies specifically designed for the unique needs of pediatric patients. This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/93767856/nuwellis-receives-uspto-notice-of-patent-allowance
$NUWE
Don't invest what you can't afford to lose. Always do your own DD. INV4$
Recent NUWE News
- Nuwellis Announces Reverse Stock Split • GlobeNewswire Inc. • 06/26/2024 12:45:00 PM
- Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™ • GlobeNewswire Inc. • 06/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 01:15:27 PM
- Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase • GlobeNewswire Inc. • 06/06/2024 01:00:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2024 03:54:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 09:22:31 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/17/2024 09:20:53 PM
- Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida • GlobeNewswire Inc. • 05/14/2024 01:00:00 PM
- Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy • GlobeNewswire Inc. • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 09:28:54 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/08/2024 09:26:11 PM
- Nuwellis, Inc. Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology • GlobeNewswire Inc. • 05/02/2024 01:00:00 PM
- Nuwellis Announces Closing of $2.7 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 10:09:12 PM
- Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 08:41:07 PM
- Nuwellis Announces Pricing of $2.7 Million Public Offering • GlobeNewswire Inc. • 04/26/2024 01:17:51 PM
- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health • GlobeNewswire Inc. • 04/09/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 09:08:24 PM
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 03/07/2024 02:08:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 05:02:05 PM
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 • GlobeNewswire Inc. • 02/27/2024 02:00:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM